Treace Medical Reports Fourth Quarter Earnings for 2025
Treace Medical (TMCI) reported a fourth-quarter revenue of $62.5 million, down 9% year-over-year due to product mix shifts toward lower-priced offerings. The company posted a net loss of $9.4 million or $0.15 per share compared to the prior year's $0.5 million loss. Adjusted EBITDA declined significantly from $11.1 million in Q4 2024 to $6.2 million, but full-year adjusted EBITDA improved by 64%.
Tickers: $TMCI
Topics: adjusted EBITDA cash burn guidance net loss revenue